ARCH Venture Fund IX, L.P. 13D and 13G filings for Beam Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:55 pm Sale |
2024-12-31 | 13G | Beam Therapeutics Inc. BEAM |
ARCH Venture Fund IX, L.P. | 4,600,747 5.600% |
-902,907 (-16.41%) |
Filing |
| 2024-02-14 3:18 pm Sale |
2023-12-31 | 13G | Beam Therapeutics Inc. BEAM |
ARCH Venture Fund IX, L.P. | 5,503,654 6.800% |
-367,496 (-6.26%) |
Filing |
| 2022-02-14 12:04 pm Sale |
2021-12-31 | 13G | Beam Therapeutics Inc. BEAM |
ARCH Venture Fund IX, L.P. | 5,871,150 8.600% |
-2,371,889 (-28.77%) |
Filing |
| 2021-02-02 4:13 pm Purchase |
2020-12-31 | 13G | Beam Therapeutics Inc. BEAM |
ARCH Venture Fund IX, L.P. | 8,243,039 13.500% |
8,243,039 (New Position) |
Filing |